SABSW • NASDAQ
SAB Biotherapeutics, Inc.
$0.04
Stock Details
| Market Cap | 382,985 |
|---|---|
| Day Change | 0.0088 (31.43%) |
| Volume | 8,297 |
| Avg Volume | 26,413.5 |
| Price Range | 0.0286-0.0477 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Financial Overview
| 52 Week High | 0.18 |
|---|---|
| 52 Week High Date | 2025-07-21 |
| 52 Week Low | 0.0205 |
| 52 Week Low Date | 2025-03-24 |
| 10D Avg Trading Vol | 0.0278 |
| YTD Price Return Daily | -54.0505 |
| MTD Price Return Daily | -11.509 |